The growth in the federal investment in research on Alzheimer’s and related dementias has expanded NIA’s budget and scientific reach. The federal planning effortopens in new window on Alzheimer’s research, care, and services has set an ambitious goal of a prevention and treatment for Alzheimer’s disease by 2025. What are some most promising discoveries that are advancing the science?
Through the recent substantial federal investments in research, NIA continues to advance scientific growth and discovery to improve the diagnosis, treatment, and care of those living with dementia. NIA-supported scientists are identifying and testing new drug candidates, advancing comprehensive models of care, developing new biomarker tests, exploring disease risk and protective factors throughout the life course that might serve as targets for preventive interventions, examining disparities in dementia prevalence as well as disparities in access to and quality of dementia care, and improving the understanding of the role of genetics and other disease mechanisms. We also have developed programs to make data, knowledge, and research tools widely available to all researchers.
NIA currently supports more than 40 trials testing drug candidates that target many different aspects of the disease, and more than 100 trials testing behavioral and lifestyle interventionsopens in new window. These include studies of the impact of physical activity, cognitive training, blood pressure control, and other behavioral changes on delaying cognitive decline and preventing mild cognitive impairment and dementia.
To better understand the etiology of the disease and to distinguish its manifestation from changes associated with normal cognitive aging, NIA has invested in a range of approaches to elucidate and measure early psychological changes in the disease trajectory. These include changes in decision-makingopens in new window and emotional function as well as memory and other cognitive functions. We also are sponsoring a major initiative to enhance our ability to detect cognitive change via mobile devicesopens in new window and use these tools to inform prevention and treatment strategies for maintaining cognitive health.
Additionally, the federal investment has enabled significant recent progress in developing, testing, and validating biomarkers for diagnosing Alzheimer’s and related dementias. These technological advances have helped scientists discover that changes in the brain that occur during Alzheimer’s are evident long before a person shows outward signs of cognitive impairment or dementia. Other research has shown that some changes in cognition associated with APOE e4 status arise even in adolescence (Reynolds, et al., 2019) and personality features predictive of future dementia can be detected by age 18 (Chapman et al., 2020). Together with sensitive measures of cognition and function, these biomarkers will play an important part in prevention trials that aim to determine whether the onset of cognitive decline or dementia can be delayed or its progression slowed at early stages of the life course, before the onset of dementia symptoms.
A new Network on Resilience and Reserveopens in new window is involved in investigating how experiences or exposures earlier in life that are prospectively associated with improvements in cognitive outcomes (and thus reductions in dementia) later in life. This network is one of many NIA transdisciplinary efforts focused on resilience in agingopens in new window.
NIA also has a long history of supporting research on dementia caregiving and dementia care. NIA recently expanded the network of Edward R. Roybal Centers for Translational Research in the Behavioral and Social Sciences of Agingopens in new window to include a group of centers designed to serve as an incubator for new dementia care and caregiving interventions. The purpose of the network is to translate findings from basic behavioral and social research into evidence-based interventions and programs that can be shared and implemented in the community. Another recently funded program is NIA’s Imbedded Pragmatic Alzheimer’s Disease and Related Dementias Clinical Trials Collaboratoryopens in new window, which is designed to bolster the nation’s capacity to conduct pragmatic clinical trials to improve dementia care within health care systems. Through this effort, researchers will test care interventions in real-world settings such as hospitals, assisted living facilities, nursing homes, and adult day centers.
With the steady growth in the number of human studies comes the urgent need to recruit far more participants who represent the diversity of the U.S. population. NIH invests in a range of methods, resources, and research to optimize recruitment efforts. NIH recently funded eight projects at research institutions nationwide to help inform scientists about how to overcome barriers to enrolling and retaining research participants from underserved communities. These projects include approaches to build trust in communities and engage specific ethnic and racial groups in Alzheimer’s and related dementias research.